We hypothesized that the combination treatment of anti-CTLA-4 monoclonal antibody and MUC1 mRNA nanovaccine may reduce immunosuppressive TEM, normalize tumor vasculature and inhibit tumor-promoting signaling pathways to achieve increased anti-tumor CTL activity and enhanced inhibition of TNBC growth. The gene discussed is MUC1; the disease is neoplasm.